COEP (Coeptis Therapeutics Holdings) FCF Margin %: -195.82% (As of Dec. 2025)

What is Coeptis Therapeutics Holdings FCF Margin %?

Coeptis Therapeutics Holdings COEP +1.52% 12 FCF Margin % is -195.82% as of Dec. 2025. GuruFocus rates COEP with a GF Score™ of 12/100. Among 959 Biotechnology companies, Coeptis Therapeutics Holdings ranks worse than 74.97% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Coeptis Therapeutics Holdings's Free Cash Flow for the three months ended in Dec. 2025 was $-1.69 Mil. Coeptis Therapeutics Holdings's Revenue for the three months ended in Dec. 2025 was $0.86 Mil. Therefore, Coeptis Therapeutics Holdings's FCF Margin % for the quarter that ended in Dec. 2025 was -195.82%.

As of today, Coeptis Therapeutics Holdings's current FCF Yield % is -8.43%.

The historical rank and industry rank for Coeptis Therapeutics Holdings's FCF Margin % or its related term are showing as below:

COEP' s FCF Margin % Range Over the Past 10 Years
Min: -10116.13 Med: -8318.67 Max: -631.18
Current: -631.18

During the past 6 years, the highest FCF Margin % of Coeptis Therapeutics Holdings was -631.18%. The lowest was -10116.13%. And the median was -8318.67%.

COEP's FCF Margin % is ranked worse than
74.97% of 959 companies
in the Biotechnology industry
Industry Median: -84.65 vs COEP: -631.18

Coeptis Therapeutics Holdings FCF Margin % Related Terms

Coeptis Therapeutics Holdings FCF Margin % Historical Data

* Premium members only.

The historical data trend for Coeptis Therapeutics Holdings's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coeptis Therapeutics Holdings FCF Margin % Chart

Coeptis Therapeutics Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

FCF Margin %

Get a 7-Day Free Trial

-8,318.67

0.00

-631.18

Coeptis Therapeutics Holdings Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
FCF Margin %	Get a 7-Day Free Trial															0.00	-3,755.56	-1,192.54	-908.02	-195.82

COEP vs ANIX, COYA, PMN: FCF Margin % Comparison

For the Biotechnology subindustry, Coeptis Therapeutics Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coeptis Therapeutics Holdings FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coeptis Therapeutics Holdings's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Coeptis Therapeutics Holdings's FCF Margin % falls into.

Save Embed

12GF Score

Coeptis Therapeutics Holdings Inc COEP

FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Coeptis Therapeutics Holdings FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Coeptis Therapeutics Holdings's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-8.603	/	1.363
	=	-631.18 %

Coeptis Therapeutics Holdings's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2025 )	/	Revenue (Q: Dec. 2025 )
	=	-1.688	/	0.862
	=	-195.82 %

Frequently Asked Questions Learn more about FCF Margin % →

What does a FCF Margin % of -195.82% mean?

Coeptis Therapeutics Holdings (COEP) has a FCF Margin % of -195.82% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Coeptis Therapeutics Holdings and its competitors. According to the industry distribution chart, Coeptis Therapeutics Holdings ranks #719 out of 959 companies in the Biotechnology industry, placing it in the top 75%.

Is Coeptis Therapeutics Holdings' FCF Margin % too high?

Coeptis Therapeutics Holdings' current FCF Margin % is -195.82%. Based on the distribution chart, Coeptis Therapeutics Holdings ranks #719 out of 959 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Coeptis Therapeutics Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.

How does Coeptis Therapeutics Holdings' FCF Margin % compare to ANIX and COYA?

According to the Biotechnology industry distribution chart, Coeptis Therapeutics Holdings ranks #719 out of 959 companies for FCF Margin %. This places Coeptis Therapeutics Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good FCF Margin % for a Biotechnology company?

A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high FCF Margin % mean?

A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Coeptis Therapeutics Holdings and its competitors. Coeptis Therapeutics Holdings's current FCF Margin % is -195.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Coeptis Therapeutics Holdings stock overvalued right now?

Coeptis Therapeutics Holdings (COEP) has a current FCF Margin % of -195.82%. The current FCF Margin % is -195.82%. Coeptis Therapeutics Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is FCF Margin % calculated?

FCF Margin % is calculated from a company's financial statements. For Coeptis Therapeutics Holdings (COEP), the current FCF Margin % is -195.82% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Coeptis Therapeutics Holdings Business Description

Industry Healthcare Biotechnology

Comparable Companies ANIX COYA PMN TTRX GUTS PEPG NRXP IFRX INO RANI VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ASX:CSL ALNY ONC XKRX:068270 INSM

Address 105 Bradford Road, Suite 420, Wexford, PA, USA, 15090

Website https://www.coeptistx.com

Coeptis Therapeutics Holdings Inc is a biopharmaceutical and technology company. The biopharmaceutical division focuses on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its research and development efforts. The technology division focuses on enhancing operational capabilities through technologies. This division features AI-powered marketing software and robotic process automation tools designed to optimize business processes and improve overall efficiency. It derives the majority of the revenue from the Technology segment.

12GF Score

Get the complete analysis for COEP

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.40

Price

View COEP Analysis

See FCF Margin % data for all stocks →